Formulation of tunable size PLGA-PEG nanoparticles for drug delivery using microfluidic technology.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Drug Delivery Systems*; Breast Neoplasms/*drug therapy ; Drug Carriers/*chemistry ; Microfluidics/*methods ; Nanoparticles/*administration & dosage ; Polyesters/*chemistry ; Polyethylene Glycols/*chemistry ; Polymers/*chemistry; Breast Neoplasms/pathology ; Female ; Humans ; MCF-7 Cells ; Nanoparticles/chemistry
    • Abstract:
      Amphiphilic block co-polymer nanoparticles are interesting candidates for drug delivery as a result of their unique properties such as the size, modularity, biocompatibility and drug loading capacity. They can be rapidly formulated in a nanoprecipitation process based on self-assembly, resulting in kinetically locked nanostructures. The control over this step allows us to obtain nanoparticles with tailor-made properties without modification of the co-polymer building blocks. Furthermore, a reproducible and controlled formulation supports better predictability of a batch effectiveness in preclinical tests. Herein, we compared the formulation of PLGA-PEG nanoparticles using the typical manual bulk mixing and a microfluidic chip-assisted nanoprecipitation. The particle size tunability and controllability in a hydrodynamic flow focusing device was demonstrated to be greater than in the manual dropwise addition method. We also analyzed particle size and encapsulation of fluorescent compounds, using the common bulk analysis and advanced microscopy techniques: Transmission Electron Microscopy and Total Internal Reflection Microscopy, to reveal the heterogeneities occurred in the formulated nanoparticles. Finally, we performed in vitro evaluation of obtained NPs using MCF-7 cell line. Our results show how the microfluidic formulation improves the fine control over the resulting nanoparticles, without compromising any appealing property of PLGA nanoparticle. The combination of microfluidic formulation with advanced analysis methods, looking at the single particle level, can improve the understanding of the NP properties, heterogeneities and performance.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      Macromol Biosci. 2011 May 12;11(5):576-89. (PMID: 21188686)
      J Biomed Mater Res. 2000 Jun 5;50(3):388-96. (PMID: 10737881)
      Cell Biol Int. 2015 Aug;39(8):881-90. (PMID: 25790433)
      Cancers (Basel). 2019 Nov 25;11(12):. (PMID: 31769416)
      Adv Drug Deliv Rev. 2006 Dec 1;58(14):1456-9. (PMID: 17070960)
      J Am Chem Soc. 2012 Feb 1;134(4):2139-47. (PMID: 22191645)
      Adv Drug Deliv Rev. 2018 Mar 15;128:54-83. (PMID: 28801093)
      J Phys Chem B. 2018 Jul 19;122(28):7080-7090. (PMID: 29927603)
      Pharm Dev Technol. 2017 Sep;22(6):836-843. (PMID: 27494230)
      Nanoscale. 2019 Jan 3;11(2):383-406. (PMID: 30560970)
      Adv Colloid Interface Sci. 2018 Mar;253:1-22. (PMID: 29478671)
      Adv Drug Deliv Rev. 2011 Mar 18;63(3):170-83. (PMID: 20965219)
      Int J Pharm. 2019 Dec 15;572:118733. (PMID: 31689481)
      RSC Adv. 2019 Jan 15;9(4):2055-2072. (PMID: 35516107)
      Drug Deliv. 2005 Jan-Feb;12(1):15-20. (PMID: 15801716)
      Nanomedicine. 2015 Oct;11(7):1603-11. (PMID: 25989200)
      J Control Release. 2000 Sep 3;68(3):419-31. (PMID: 10974396)
      Pharm Res. 2016 Oct;33(10):2373-87. (PMID: 27299311)
      Macromol Biosci. 2020 Apr;20(4):e1900427. (PMID: 32077622)
      ACS Appl Mater Interfaces. 2013 Oct 9;5(19):9746-51. (PMID: 24018018)
      Pharmaceutics. 2018 Dec 06;10(4):. (PMID: 30563197)
      Adv Drug Deliv Rev. 2011 Mar 18;63(3):136-51. (PMID: 20441782)
      Acta Biomater. 2018 Jun;73:38-51. (PMID: 29653217)
      Nanoscale. 2016 Jul 7;8(25):12430-43. (PMID: 26864887)
      Nat Biotechnol. 2015 Sep;33(9):941-51. (PMID: 26348965)
      Int J Pharm. 2008 Dec 8;364(2):298-327. (PMID: 18621492)
      Int J Pharm. 2001 Jun 19;221(1-2):143-52. (PMID: 11397575)
      Adv Drug Deliv Rev. 2018 Mar 15;128:101-114. (PMID: 29277543)
      Chem Rev. 2016 Feb 24;116(4):2602-63. (PMID: 26854975)
      Mol Pharm. 2020 Dec 7;17(12):4421-4434. (PMID: 33213144)
      Biomaterials. 2013 Dec;34(38):10238-48. (PMID: 24070569)
      Lab Chip. 2017 Jan 17;17(2):209-226. (PMID: 27991629)
      Nat Rev Cancer. 2017 Jan;17(1):20-37. (PMID: 27834398)
      Angew Chem Int Ed Engl. 2013 Feb 25;52(9):2463-8. (PMID: 23362104)
      Polymers (Basel). 2011 Sep 1;3(3):1377-1397. (PMID: 22577513)
      Nano Lett. 2008 Sep;8(9):2906-12. (PMID: 18656990)
      Nat Commun. 2017 Nov 23;8(1):1747. (PMID: 29170511)
      Beilstein J Nanotechnol. 2019 Nov 19;10:2280-2293. (PMID: 31807413)
      Chem Eng Sci. 2015 Mar 24;125:75-84. (PMID: 25684779)
      Science. 1990 Sep 28;249(4976):1527-33. (PMID: 2218494)
      Adv Drug Deliv Rev. 2018 May;130:17-38. (PMID: 30009886)
      Int J Pharm. 2006 Jan 3;307(1):93-102. (PMID: 16303268)
      Adv Drug Deliv Rev. 2019 Mar 15;143:68-96. (PMID: 31022434)
      Int J Pharm X. 2019 Aug 13;1:100030. (PMID: 31517295)
      Colloids Surf B Biointerfaces. 2021 May;201:111598. (PMID: 33618081)
      ACS Nano. 2013 Dec 23;7(12):10671-80. (PMID: 24215426)
      J Control Release. 2005 Dec 5;109(1-3):169-88. (PMID: 16289422)
      Biomaterials. 2014 Apr;35(13):4088-98. (PMID: 24513320)
      J Intern Med. 2021 Sep;290(3):486-498. (PMID: 33480120)
      Chem Soc Rev. 2012 Apr 7;41(7):2539-44. (PMID: 22310807)
      Eur J Pharm Sci. 2013 Feb 14;48(3):416-27. (PMID: 23262059)
      Pharmacogenet Genomics. 2011 Jul;21(7):440-6. (PMID: 21048526)
      Macromolecules. 2020 May 26;53(10):3643-3654. (PMID: 32831403)
      AAPS PharmSciTech. 2014 Aug;15(4):822-33. (PMID: 24687241)
      J Colloid Interface Sci. 2016 Aug 1;475:136-148. (PMID: 27163840)
      Int J Pharm. 2006 Nov 15;325(1-2):172-9. (PMID: 16887303)
      J Control Release. 2019 Jun 28;304:125-134. (PMID: 31071374)
      Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51. (PMID: 26456916)
      Int J Pharm. 2018 Sep 5;548(1):530-539. (PMID: 30009983)
      J Drug Deliv. 2014;2014:620464. (PMID: 24616812)
      Int J Nanomedicine. 2013;8:747-65. (PMID: 23459088)
      Nanoscale. 2016 Jan 28;8(4):1746-69. (PMID: 26731460)
      Annu Rev Biomed Eng. 2012;14:1-16. (PMID: 22524388)
      Lab Chip. 2015 Dec 7;15(23):4383-6. (PMID: 26486277)
      Adv Drug Deliv Rev. 1997 Oct 13;28(1):5-24. (PMID: 10837562)
      Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):15919-24. (PMID: 24046373)
      J Control Release. 2020 Mar 10;319:276-284. (PMID: 31884098)
      J Control Release. 2002 Feb 19;79(1-3):123-35. (PMID: 11853924)
      Phys Rev Lett. 2003 Sep 12;91(11):118302. (PMID: 14525460)
      Expert Opin Drug Deliv. 2016 Oct;13(10):1447-60. (PMID: 27253154)
    • Accession Number:
      0 (Drug Carriers)
      0 (Polyesters)
      0 (Polymers)
      0 (polyethylene glycol-poly(lactide-co-glycolide))
      3WJQ0SDW1A (Polyethylene Glycols)
    • Publication Date:
      Date Created: 20210618 Date Completed: 20211102 Latest Revision: 20240402
    • Publication Date:
      20240402
    • Accession Number:
      PMC8213178
    • Accession Number:
      10.1371/journal.pone.0251821
    • Accession Number:
      34143792